ArticleMedical mycology2026
Protective effects of cell-free supernatants from a kefir-derived microbial consortium against multidrug-resistant Candida glabrata associated with vulvovaginal candidiasis.
Article in Medical mycology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vulvovaginal candidiasis (VVC) caused by non-albicans Candida species, particularly Candida glabrata, is increasingly associated with treatment failure due to intrinsic or acquired resistance to antifungal drugs. In this study, we explored the anticandidal activity of a postbiotic cell-free supernatant (CFS) obtained from a microbial consortium isolated from homemade kefir (Lactococcus lactis subsp. hordniae, Lactococcus lactis subsp. lactis, and Pichia kudriavzevii) against one reference strain and two multidrug-resistant clinical isolates of C. glabrata. Antifungal susceptibility assays showed a fungistatic effect of CFS (Minimum Inhibitory Concentration [MIC] ≥ 500 µg/ml). Pre-treatment with sub-MIC concentrations (100 µg/ml) of CFS significantly reduced C. glabrata planktonic growth and cell surface hydrophobicity, as well as A-431 vaginal epithelial cell damage. Although total biofilm biomass of C. glabrata was not markedly affected by pre-treatment, metabolic activity was significantly decreased, together with downregulation of key virulence genes (ALS3, ERG11, and FKS1). Subsequently, we explored the effect of the CFS on the inhibition and eradication of biofilms derived from pretreated cells, showing a more marked effect compared to biofilms from untreated cells. Furthermore, in pre-treated fungal cells, the CFS almost completely abolished invasive capacity, reducing invasion in epithelial cell model and restored wound healing capacity following infection. Additionally, CFS modulated the host inflammatory response by reducing the expression of pro-inflammatory cytokines in A-431 cells. Overall, the kefir-derived postbiotic attenuated major virulence traits of C. glabrata and promoted epithelial protection, providing preliminary evidence supporting its potential as a complementary approach for VVC prevention and management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.